A panel of experts not affiliated with the US Food and Drug Administration (FDA) recommended that the US Food and Drug Administration approve the sale of over-the-counter nicotine oral sprays in the United States.
The spray was produced by the pharmaceutical giant GlaxoSmithKline (GSK), developed jointly by GlaxoSmithKline and Johnson & Johnson, and sold in 45 countries outside the United States.
Each spray can provide 1 mg of nicotine (about one-twelfth of a cigarette) to the user. It is designed to help people quit smoking, just like traditional smoking cessation nicotine gum, patches and even e-cigarettes.
It is worth noting that users may be addicted to the spray.
With the wave of restrictive laws in various regions of the United States, some sales of e-cigarettes have been banned. Some experts predict that e-cigarettes in any way will be greatly affected in such an environment.
If the US Food and Drug Administration finally approves this over-the-counter oral spray, it is even expected to usurp the throne of e-cigarettes.
Just as GlaxoSmithKline tried to promote the global cultural peak of oral fresheners in the mid-1990s, it plans to launch this new product during the period of suppressing electronic cigarettes with the US policy, making its ambition obtrusive.